Physician profile
Jack R Harris
NPI 1467445452
$5,348.56
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $462 · 2021: $1,457 · 2022: $1,502 · 2023: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,176.14 | 2019-2023 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $807.47 | 2019-2023 | Dupixent |
| Kaleo, INC. | $467.64 | 2020-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $415.82 | 2021-2023 | Takhzyro, Cuvitru |
| Grifols USA, LLC | $378.81 | 2020-2023 | Xembify, Gamunex-C |
| Glaxosmithkline, LLC. | $376.24 | 2020-2023 | Trelegy Ellipta, Nucala |
| Pfizer INC. | $293.88 | 2019-2023 | |
| Genzyme Corporation | $289.87 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.64 | 2019-2022 | |
| Genentech USA, INC. | $158.48 | 2019-2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $149.29 | 2019-2021 | |
| Csl Behring | $131.52 | 2019-2023 | Hizentra |
| Sanofi-Aventis U.S. LLC | $129.64 | 2019-2022 | |
| Pharming Healthcare, INC. | $100.27 | 2019-2023 | Ruconest |
| Biocryst US Sales Co., LLC | $97.39 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.00 | 2019 | |
| Hikma Pharmaceuticals USA | $33.56 | 2023 | Ryaltris |
| Optinose US, INC. | $28.45 | 2019 | |
| Incyte Corporation | $26.34 | 2022 | |
| Uswm, LLC | $20.64 | 2021 | |
| Merck Sharp & Dohme LLC | $18.92 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.